Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Lurbinectedin + Radiation in Soft Tissue Sarcoma
NCT06217536Phase 2Withdrawn
- Sponsor
- University of California, San Francisco
- Start
- Oct 2024
- Primary completion
- May 2026
- Modality
- Classical Binding Small Molecules, DNA Intercalators/Alkylators
01
Overview
A Phase 2 trial of lurbinectedin in soft tissue sarcoma (STS), sponsored by University of California, San Francisco. Planned start Oct 2024; status: withdrawn.
02
Drugs
lurbinectedin
03
Conditions
soft tissue sarcoma (STS)
Beyond the preview
Go deeper on NCT06217536.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06217536.